License Agreements and Services Agreement with Ionis (Tables)

3 Months Ended

Mar. 31, 2019

Schedule Of Net Loss Share Related to Commercial Activities Under TTR Agreement

A summary of the loss share related to the commercial activities under the TTR Agreement is as follows:

	Three Months Ended March 31,
	2019
Net losses incurred by the collaboration related to the commercial activities under the TTR Agreement	$	(15,098	)
Ionis' share of commercial losses under the TTR Agreement reflected in our consolidated statements of operations		(9,056	)
Akcea's share of commercial losses under the TTR Agreement reflected in our consolidated statements of operations	$	(6,042	)

Schedule Of Development Expenses Related to TTR Agreement

A summary of the development expenses related to the TTR Agreement is as follows:

	Three Months Ended March 31,
	2019
Total development expense incurred by the collaboration related to development activities under the TTR Agreement	$	(14,380	)
Akcea's share of TTR development expense reflected in research and development expense in our consolidated statements of operations	$	(6,133	)

Amounts Recorded Related to Transactions with Ionis Including Amounts Related to TTR Licensing Transaction

The following table summarizes the amounts recorded related to transactions with Ionis including amounts related to the TTR licensing transaction for the following periods (in thousands):

	Three Months Ended March 31,
	2019			2018
Operating expenses:
Services performed by Ionis	$	1,075		$	1,945
Active pharmaceutical ingredient manufactured by Ionis		—			5,229
Sublicensing expenses		75,000			—
Out-of-pocket expenses paid by Ionis		1,571			6,236
Less: commercial share of loss in connection with the TTR license transaction		(9,056	)		—
Less: R&D share of loss in connection with the TTR license transaction		(796	)		—
Total operating expenses generated by transactions with Ionis		67,794			13,410
Less: distribution to Ionis		13,492			—
Total charges generated by transactions with Ionis		81,286			13,410
Payable balance to Ionis at the beginning of the period		18,901			14,365
Less: total amounts paid to Ionis during the period		(32,393	)		(38	)
Less: non-cash sublicensing expenses		(75,000	)		—
Total amount payable (receivable) to Ionis at period end	$	(7,206	)	$	27,737